Liquidia Corporation found using ticker (LQDA) now have 5 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 6 and 4 with the average target price sitting at 5.2. Given that the stocks previous close was at 3.13 this indicates there is a potential upside of 66.1%. The 50 day MA is 3.32 while the 200 day moving average is 5.37. The market cap for the company is $130m. You can visit the company’s website by visiting: http://www.liquidia.com
The potential market cap would be $216m based on the market concensus.
Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
